Immunoselected STRO-3 Mesenchymal Precursor Cells Reduce Inflammation and Improve Clinical Outcomes in a Large Animal Model of Monoarthritis

Overview

Journal Stem Cell Res Ther

Publisher Biomed Central

Date 2017 Feb 9

PMID 28173831

Citations 10

Authors

Anwar Abdalmula

Laura M Dooley

Claire Kaufman

Elizabeth A Washington

Jacqueline V House

Barbara A Blacklaws

Peter Ghosh

Silviu Itescu

Simon R Bailey

Wayne G Kimpton

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this study was to investigate the therapeutic efficacy of intravenously administered immunoselected STRO-3 + mesenchymal precursor cells (MPCs) on clinical scores, joint pathology and cytokine production in an ovine model of monoarthritis.

Methods: Monoarthritis was established in 16 adult merino sheep by administration of bovine type II collagen into the left hock joint following initial sensitization to this antigen. After 24 h, sheep were administered either 150 million allogeneic ovine MPCs (n = 8) or saline (n = 8) intravenously (IV). Lameness, joint swelling and pain were monitored and blood samples for leukocytes and cytokine levels were collected at intervals following arthritis induction. Animals were necropsied 14 days after arthritis induction and gross and histopathological evaluations were undertaken on tissues from the arthritic (left) and contralateral (right) joints.

Results: MPC-treated sheep demonstrated significantly reduced clinical signs of lameness, joint pain and swelling compared with saline controls. They also showed decreased cartilage erosions, synovial stromal cell activation and angiogenesis. This was accompanied by decreased infiltration of the synovial tissues by CD4 lymphocytes and CD14 monocytes/macrophages. Over the 3 days following joint arthropathy induction, the numbers of neutrophils circulating in the blood and plasma concentrations of activin A were significantly reduced in animals administered MPCs.

Conclusions: The results of this study have demonstrated the capacity of IV-administered MPCs to mitigate the clinical signs and some of the inflammatory mediators responsible for joint tissue destruction in a large animal model of monoarthritis.

Citing Articles

Mesenchymal Stem Cells and Tissue Bioengineering Applications in Sheep as Ideal Model.

Muniz T, Rossi M, de Vasconcelos Machado V, Alves A Stem Cells Int. 2024; 2024:5176251.

PMID: 39465229 PMC: 11511598. DOI: 10.1155/2024/5176251.

Unveiling heterogeneity in MSCs: exploring marker-based strategies for defining MSC subpopulations.

Chen S, Liang B, Xu J J Transl Med. 2024; 22(1):459.

PMID: 38750573 PMC: 11094970. DOI: 10.1186/s12967-024-05294-5.

Identification of a novel, MSC-induced macrophage subtype via single-cell sequencing: implications for intervertebral disc degeneration therapy.

Koroth J, Chitwood C, Kumar R, Lin W, Reves B, Boyce T Front Cell Dev Biol. 2024; 11:1286011.

PMID: 38274272 PMC: 10808728. DOI: 10.3389/fcell.2023.1286011.

Stem cell therapy for heart failure in the clinics: new perspectives in the era of precision medicine and artificial intelligence.

Chowdhury M, Zhang J, Rizk R, Chen W Front Physiol. 2024; 14:1344885.

PMID: 38264333 PMC: 10803627. DOI: 10.3389/fphys.2023.1344885.

Assessment of mesenchymal stem/stromal cell-based therapy in K/BxN serum transfer-induced arthritis.

Lopez-Santalla M, Conde C, Rodriguez-Trillo A, Garin M Front Immunol. 2022; 13:943293.

PMID: 36300108 PMC: 9589432. DOI: 10.3389/fimmu.2022.943293.

References

Morel J, Park C, Zhu K, Kumar P, Ruth J, Koch A . Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J Biol Chem. 2002; 277(38):34679-91. DOI: 10.1074/jbc.M206337200. View

Rosloniec E, Cremer M, Kang A, Myers L . Collagen-induced arthritis. Curr Protoc Immunol. 2008; Chapter 15:15.5.1-15.5.24. DOI: 10.1002/0471142735.im1505s20. View

Colmegna I, Ohata B, Menard H . Current understanding of rheumatoid arthritis therapy. Clin Pharmacol Ther. 2012; 91(4):607-20. DOI: 10.1038/clpt.2011.325. View

Little C, Smith M, Cake M, Read R, Murphy M, Barry F . The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in sheep and goats. Osteoarthritis Cartilage. 2010; 18 Suppl 3:S80-92. DOI: 10.1016/j.joca.2010.04.016. View

Sozzani S, Musso T . The yin and yang of Activin A. Blood. 2011; 117(19):5013-5. DOI: 10.1182/blood-2011-03-342691. View

Pickens S, Volin M, Mandelin 2nd A, Kolls J, Pope R, Shahrara S . IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol. 2010; 184(6):3233-41. PMC: 2857761. DOI: 10.4049/jimmunol.0903271. View

Uccelli A, Moretta L, Pistoia V . Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2009; 8(9):726-36. DOI: 10.1038/nri2395. View

Smith M, Cake M, Ghosh P, Schiavinato A, Read R, Little C . Significant synovial pathology in a meniscectomy model of osteoarthritis: modification by intra-articular hyaluronan therapy. Rheumatology (Oxford). 2008; 47(8):1172-8. PMC: 2468886. DOI: 10.1093/rheumatology/ken219. View

Griffiths R, Pettipher E, Koch K, Farrell C, Breslow R, Conklyn M . Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci U S A. 1995; 92(2):517-21. PMC: 42772. DOI: 10.1073/pnas.92.2.517. View

10.

Tobin L, Healy M, English K, Mahon B . Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease. Clin Exp Immunol. 2013; 172(2):333-48. PMC: 3628335. DOI: 10.1111/cei.12056. View

11.

Gronthos S, Zannettino A, Hay S, Shi S, Graves S, Kortesidis A . Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci. 2003; 116(Pt 9):1827-35. DOI: 10.1242/jcs.00369. View

12.

Mao F, Xu W, Qian H, Zhu W, Yan Y, Shao Q . Immunosuppressive effects of mesenchymal stem cells in collagen-induced mouse arthritis. Inflamm Res. 2009; 59(3):219-25. DOI: 10.1007/s00011-009-0090-y. View

13.

Maddox J, Mackay C, Brandon M . Surface antigens, SBU-T4 and SBU-T8, of sheep T lymphocyte subsets defined by monoclonal antibodies. Immunology. 1985; 55(4):739-48. PMC: 1453767. View

14.

Kaplan M . Role of neutrophils in systemic autoimmune diseases. Arthritis Res Ther. 2013; 15(5):219. PMC: 3978765. DOI: 10.1186/ar4325. View

15.

Firestein G . Evolving concepts of rheumatoid arthritis. Nature. 2003; 423(6937):356-61. DOI: 10.1038/nature01661. View

16.

Park S, Kim K, Kim W, Cho C . Interaction of mesenchymal stem cells with fibroblast-like synoviocytes via cadherin-11 promotes angiogenesis by enhanced secretion of placental growth factor. J Immunol. 2014; 192(7):3003-10. DOI: 10.4049/jimmunol.1302177. View

17.

Martin H, Nash A, Andrews A . Cloning and characterisation of an ovine interleukin-10-encoding cDNA. Gene. 1995; 159(2):187-91. DOI: 10.1016/0378-1119(95)00123-n. View

18.

Koenders M, Marijnissen R, Devesa I, Lubberts E, Joosten L, Roth J . Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheum. 2011; 63(8):2329-39. DOI: 10.1002/art.30418. View

19.

Mills K, Dungan L, Jones S, Harris J . The role of inflammasome-derived IL-1 in driving IL-17 responses. J Leukoc Biol. 2012; 93(4):489-97. DOI: 10.1189/jlb.1012543. View

20.

Lee S, Kwok S, Son H, Ryu J, Kim E, Oh H . IL-17-mediated Bcl-2 expression regulates survival of fibroblast-like synoviocytes in rheumatoid arthritis through STAT3 activation. Arthritis Res Ther. 2013; 15(1):R31. PMC: 3672783. DOI: 10.1186/ar4179. View